The Wall Street Journal

The obesity market is growing just fine – but investors want to know what’s next

The obesity market is growing just fine – but investors want to know what’s next
On paper, Ozempic owner Novo has an extensive pipeline, with several next-generation drugs in development.
The Wall Street Journal
By David WainerInvestors in the obesity drug market can breathe a sigh of relief – but not for long.On Wednesday, Novo Nordisk calmed fears of slowing demand, projecting a robust 20% increase in companywide sales at the midpoint of its 2025 guidance. While slightly slower than last year’s growth, that pace remains impressive in the world of pharmaceutical companies. Eli Lilly, meanwhile, on Thursday confirmed an earlier projection of about 32% revenue growth this year.After months of choppy stock performance driven by fears of a mar...

More Finance

Govt eagle-eyed on ComCom interchange fees decision
Finance

Govt eagle-eyed on ComCom interchange fees decision

Open banking depends on sustainable interchange fees, Minister Scott Simpson says.

Pattrick Smellie 11 Apr 2025
Risky business? Why $500m for Kiwibank is causing concern
Finance

Risky business? Why $500m for Kiwibank is causing concern

Being state-owned doesn't mean you get a free $500m lunch, expert says.

Legal shots fired in FNZ employee shareholder stoush
Finance

Legal shots fired in FNZ employee shareholder stoush

Employees claim oppression and put directors on notice.

Victoria Young 09 Apr 2025
Credit card issuers fear ComCom proposals
Finance

Credit card issuers fear ComCom proposals

The proposed regulations will stifle banking competition, says Mastercard.

Pattrick Smellie 02 Apr 2025